Literature DB >> 30663824

The effect of memantine in adult patients with attention deficit hyperactivity disorder.

Soleiman Mohammadzadeh1, Tina Kaveh Ahangari2, Fayegh Yousefi2.   

Abstract

BACKGROUND: Hyperactivity disorder and attention deficit are common neurological disorders in children and adolescents. The symptoms of hyperactivity are decreased in adults, and attention deficit is more noticeable. This study was carried out to evaluate the effect of memantine on adult patients with attention deficit hyperactivity disorder (ADHD).
MATERIALS AND METHODS: In a double-blind clinical trial study, 40 patients aged 18 to 45 years with ADHD were selected on the basis on the Diagnosis and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria, and randomly assigned memantine or placebo. Before starting the treatment, Conners' screening questionnaire was completed for each patient, and the subjects were entered the study after acquiring minimum acceptable score in the questionnaire.
RESULTS: The mean age of patients who were receiving memantine and placebo was about 34.7 ± 4.48 and 31.5 ± 7.4 years, respectively. The results have shown a significant difference in the behavior and attention deficit between the two groups treated with memantine and placebo during 6 weeks (p < 0.001). Also, there was a significant difference in the third and sixth weeks between treatment groups in hyperactivity and attention deficit index (p = 0.001).
CONCLUSION: The results of this study indicated that memantine was effective in reducing symptoms of Inattention/Memory Problems, Hyperactivity/Restlessness, Impulsivity/Emotional Lability.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  adult; attention deficit; clinical trial; hyperactivity; memantine

Mesh:

Substances:

Year:  2019        PMID: 30663824     DOI: 10.1002/hup.2687

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  2 in total

Review 1.  Memantine for autism spectrum disorder.

Authors:  Amanda Brignell; Catherine Marraffa; Katrina Williams; Tamara May
Journal:  Cochrane Database Syst Rev       Date:  2022-08-25

2.  Pharmacological Modulation of Glutamatergic and Neuroinflammatory Pathways in a Lafora Disease Mouse Model.

Authors:  Belén Mollá; Miguel Heredia; Ángela Campos; Pascual Sanz
Journal:  Mol Neurobiol       Date:  2022-07-14       Impact factor: 5.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.